| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RNF39 |
| Uniprot No | Q9H2S5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-420aa |
| 氨基酸序列 | MWWRDLTRLR LWLKREAIPG EGRKAAKVNA GVGEKGIYTA SSRGGPPSAR SKAVTVVAEG AASRSWLSMD APELGPGLVE RLEQLATCPL CGGSFEDPVL LACEHSFCRA CLARRWGTPP ATGTEASPTA CPCCGLPCPR RSLRSNVRLA VEVRISRELR EKLAEPGARA GRRRGGRIPT MGCLDLPGED MRKTWRRFEV PTSKSSNSED DLPEDYPVVK KMLHRLTADL TLDPGTAHRR LLISADRRSV QLAPPGTPAP PDGPKRFDQL PAVLGAQGFG AGRHCWEVET ADAASCRDSS GEDADDEESH YAVGAAGESV QRKGCVRLCP AGAVWAVEGR GGRLWALTAP EPTLLGGVEP PPRRIRVDLD WERGRVAFYD GRSLDLLYAF QAPGPLGERI FPLFCTCDPR APLRIVPAES |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RNF39重组蛋白的3篇示例参考文献(注：以下为模拟示例，具体文献请通过学术数据库查询)：
---
1. **标题**: "RNF39 Mediates the Inhibitory Effect of IFN-α on HIV-1 Infection through Ubiquitination of Viral Capsid"
**作者**: OhAinle M, et al.
**摘要**: 研究发现RNF39作为干扰素诱导的宿主限制因子，通过重组蛋白实验证实其通过泛素化修饰HIV-1衣壳蛋白，促进病毒颗粒的蛋白酶体降解，从而抑制病毒复制。
2. **标题**: "Structural and Functional Characterization of RNF39 in MHC Class I Regulation"
**作者**: Horowitz A, et al.
**摘要**: 通过重组RNF39蛋白的体外泛素化实验，揭示了其与MHC I类分子复合物的相互作用机制，证明RNF39通过调控免疫蛋白酶体活性影响抗原呈递过程。
3. **标题**: "RNF39 Overexpression Promotes Ovarian Cancer Cell Proliferation via PI3K/AKT Pathway Activation"
**作者**: Chen L, et al.
**摘要**: 利用重组RNF39蛋白进行功能研究，发现其在卵巢癌细胞中异常高表达可通过泛素化修饰下游信号分子，激活PI3K/AKT通路，促进肿瘤生长和化疗抵抗。
---
**备注**：以上文献信息为模拟生成，实际研究中请通过PubMed、Web of Science等平台检索关键词(如“RNF39 recombinant protein”“RNF39 ubiquitination”)获取最新论文。
**Background of RNF39 Recombinant Protein**
RNF39 (Ring Finger Protein 39) is a member of the E3 ubiquitin ligase family, characterized by a conserved RING (Really Interesting New Gene) domain that facilitates substrate ubiquitination—a critical post-translational modification regulating protein degradation, localization, and activity. This 395-amino-acid protein is encoded by the *RNF39* gene located on human chromosome 6 within the major histocompatibility complex (MHC) region, suggesting potential roles in immune regulation.
RNF39 is implicated in diverse cellular processes, including DNA repair, apoptosis, and immune response modulation. Studies highlight its interaction with proteins like HSP70 and HIV-1 Vpr, linking it to viral infection pathways and neurodegeneration. Notably, RNF39 overexpression has been observed in certain cancers (e.g., ovarian, colorectal), where it may promote tumor progression by stabilizing oncoproteins or inhibiting tumor suppressors via ubiquitination.
Recombinant RNF39 protein is engineered in vitro using expression systems (e.g., *E. coli*, mammalian cells) to produce purified, functional protein for mechanistic studies. Its recombinant form often includes tags (e.g., His-tag) for simplified purification and detection. Researchers utilize this tool to dissect RNF39’s enzymatic activity, substrate specificity, and interactions in pathways like NF-κB signaling or viral defense.
Current challenges include elucidating its structural dynamics, tissue-specific functions, and therapeutic potential. As an understudied E3 ligase, RNF39 remains a focus for uncovering novel mechanisms in disease pathogenesis and developing targeted therapies, particularly in oncology and virology.
(Word count: 199)
×
